Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 13Phase 1/2 8Phase 1 6Phase NA 1Phase 4 1Phase 2/3 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Has results × Ado-Trastuzumab Emtansine × Clear all
NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Dana-Farber Cancer Institute

Phase 1 Completed
20 enrolled 14 charts
Breast

Breast Neoplasms

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stanford University

Phase 1 Completed
18 enrolled 17 charts
Breast

Breast Neoplasms

NCT02562378 2022-02-23

THELMA

MedSIR

Phase 1 Completed
15 enrolled 39 charts
Breast

Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02038010 2020-06-29

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Northwestern University

Phase 1 Completed
17 enrolled 17 charts
Breast

Breast Neoplasms

NCT00932373 2015-08-26

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Genentech, Inc.

Phase 1 Completed
54 enrolled 25 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡